指南与共识胸部CT

特发性肺纤维化(更新版)与成人进展性肺纤维化:ATS/ERS/JRS/ALAT官方临床实践指南

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
指南 / 共识 · Am J Respir Crit Care Med · 2022-01-01

该指南由ATS、ERS、JRS和ALAT联合制定,更新了IPF的放射与病理标准,并通过GRADE方法对经支气管肺冷冻活检、基因组分类检测、抗酸药物及抗反流手术给出推荐;同时定义了进展性肺纤维化(PPF)及其放射与生理标准,并对尼达尼布和吡非尼酮给出推荐。

要点

  • 在具备适当专业技术的中心,经支气管肺冷冻活检可作为外科肺活检的可接受替代方案(条件性推荐)。
  • 不推荐抗酸药物和抗反流手术治疗IPF(条件性推荐反对)。
  • PPF定义为非IPF的ILD患者在过去一年内出现三项标准中至少两项(症状恶化、放射学进展、生理学进展),且无其他解释。

核心结论

  • 指南对IPF的经支气管肺冷冻活检、抗酸药物及抗反流手术给出条件性推荐,对基因组分类检测未作推荐;对PPF推荐尼达尼布(条件性推荐),并建议进一步研究吡非尼酮。

研究设计与样本

  • 由ATS、ERS、JRS和ALAT组成的多学科专家委员会制定,包括IPF更新和PPF两部分;IPF的放射与病理标准通过共识更新,临床问题通过系统评价和GRADE方法给出基于证据的推荐;PPF的定义及放射与生理标准通过共识确定。

诊断标准与关键数值

  • PPF定义为在非IPF的ILD患者中,过去一年内出现三项标准中至少两项(症状恶化、放射学进展、生理学进展),且无其他解释;IPF的放射与病理标准通过共识更新。

临床应用与阅片要点

  • 在具备适当专业技术的中心,可将经支气管肺冷冻活检视为外科肺活检的可接受替代方案(条件性推荐);不推荐抗酸药物和抗反流手术治疗IPF(条件性推荐反对);对PPF推荐尼达尼布(条件性推荐),并建议进一步研究吡非尼酮;对基因组分类检测未作推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results:1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions: The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022. PMID: 35486072. doi:10.1164/rccm.202202-0399ST

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。